GlobalData on MSN3d
J&Js Lazcluze/Rybrevant combination obtains European approval to treat NSCLC
The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...
The Pharma Letter3d
EC approves added use for J&J’s Lazcluze combo with Rybrevant for lung cancer
The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...
pharmaphorum3d
EU approves endometrial, lung cancer drugs from GSK and J&J
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...
FiercePharma2d
J&J stands by sales growth ambitions—and points to potential Tremfya boon—as Stelara biosimilars take hold
As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Johnson & Johnson (NYSE:JNJ) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...
PharmaTimes3d
EC approves lazertinib in combination with amivantamab for NSCLC patients
The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...
Johnson & Johnson price target lowered to $163 from $175 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Johnson & Johnson to $163 from $175 and keeps an Equal Weight rating on the shares ...